GlassScriptPhysician profile
Sara J Ambatt
NPI 1821384892
$4,757.54
in general payments reported to CMS, 2019-2025
22 companies · $1,668 in 2025
The $1,668 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $217 · 2022: $995 · 2023: $652 · 2024: $1,225 · 2025: $1,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,545.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $614.86 | 2021-2025 | Cobenfy |
| Stryker Corporation | $602.51 | 2023-2025 | Mako |
| Astrazeneca Pharmaceuticals LP | $591.68 | 2023-2025 | Tezspire, Fasenra, Calquence |
| Janssen Pharmaceuticals, INC | $414.33 | 2023-2025 | Invega Sustenna |
| Genzyme Corporation | $316.89 | 2022-2025 | |
| Corcept Therapeutics | $308.26 | 2022-2025 | Korlym |
| Boston Scientific Corporation | $278.17 | 2022-2025 | Watchman Flx |
| Scpharmaceuticals INC. | $150.00 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.62 | 2024 | |
| Agios Pharmaceuticals, INC. | $130.01 | 2025 | Pyrukynd |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2022 | |
| Ani Pharmaceuticals, INC. | $125.00 | 2024 | Purified Cortrophin Gel |
| Ucb, INC. | $125.00 | 2025 | Nayzilam |
| Alexion Pharmaceuticals, INC. | $124.99 | 2022 | |
| Sage Therapeutics, LLC | $120.00 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $119.85 | 2025 | Phasix Mesh |
| Neurelis, INC. | $104.18 | 2024 | Valtoco |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $104.02 | 2021 | |
| Mallinckrodt Hospital Products INC. | $100.00 | 2023 | Terlivaz |
| Abbott Laboratories | $71.15 | 2025 | Eterna |
| Axonics, INC. | $61.55 | 2024 | Bulkamid |
| Glaxosmithkline, LLC. | $24.47 | 2025 | Blenrep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Ambatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.